Literature DB >> 24636375

Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

J Jaime Caro1, David M Eddy2, Hong Kan3, Cheryl Kaltz4, Bimal Patel5, Randa Eldessouki6, Andrew H Briggs7.   

Abstract

The evaluation of the cost and health implications of agreeing to cover a new health technology is best accomplished using a model that mathematically combines inputs from various sources, together with assumptions about how these fit together and what might happen in reality. This need to make assumptions, the complexity of the resulting framework, the technical knowledge required, as well as funding by interested parties have led many decision makers to distrust the results of models. To assist stakeholders reviewing a model's report, questions pertaining to the credibility of a model were developed. Because credibility is insufficient, questions regarding relevance of the model results were also created. The questions are formulated such that they are readily answered and they are supplemented by helper questions that provide additional detail. Some responses indicate strongly that a model should not be used for decision making: these trigger a "fatal flaw" indicator. It is hoped that the use of this questionnaire, along with the three others in the series, will help disseminate what to look for in comparative effectiveness evidence, improve practices by researchers supplying these data, and ultimately facilitate their use by health care decision makers.
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  credibility; good practices; modeling; quality assurance; validity

Mesh:

Year:  2014        PMID: 24636375     DOI: 10.1016/j.jval.2014.01.003

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  51 in total

1.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

2.  The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2019-03-12

3.  Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).

Authors:  Michael Willis; Pierre Johansen; Andreas Nilsson; Christian Asseburg
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

Review 4.  Cost-Effectiveness of HIV Retention and Re-engagement Interventions in High-Income Countries: A Systematic Literature Review.

Authors:  Margo M Wheatley; Gregory S Knowlton; Mary Butler; Eva A Enns
Journal:  AIDS Behav       Date:  2022-01-25

5.  Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.

Authors:  Fahim Faruque; Heejung Noh; Arif Hussain; Edward Neuberger; Eberechukwu Onukwugha
Journal:  J Manag Care Spec Pharm       Date:  2019-02

6.  Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.

Authors:  Anna Hung; Julia F Slejko; Amy Lugo; Fadia Shaya; Stuart T Haines; C Daniel Mullins
Journal:  J Manag Care Spec Pharm       Date:  2019-08

7.  GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making.

Authors:  Jan L Brozek; Carlos Canelo-Aybar; Elie A Akl; James M Bowen; John Bucher; Weihsueh A Chiu; Mark Cronin; Benjamin Djulbegovic; Maicon Falavigna; Gordon H Guyatt; Ami A Gordon; Michele Hilton Boon; Raymond C W Hutubessy; Manuela A Joore; Vittal Katikireddi; Judy LaKind; Miranda Langendam; Veena Manja; Kristen Magnuson; Alexander G Mathioudakis; Joerg Meerpohl; Dominik Mertz; Roman Mezencev; Rebecca Morgan; Gian Paolo Morgano; Reem Mustafa; Martin O'Flaherty; Grace Patlewicz; John J Riva; Margarita Posso; Andrew Rooney; Paul M Schlosser; Lisa Schwartz; Ian Shemilt; Jean-Eric Tarride; Kristina A Thayer; Katya Tsaioun; Luke Vale; John Wambaugh; Jessica Wignall; Ashley Williams; Feng Xie; Yuan Zhang; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2020-09-24       Impact factor: 6.437

Review 8.  Appraisal of patient-level health economic models of severe mental illness: systematic review.

Authors:  James Altunkaya; Jung-Seok Lee; Apostolos Tsiachristas; Felicity Waite; Daniel Freeman; José Leal
Journal:  Br J Psychiatry       Date:  2021-08-19       Impact factor: 9.319

Review 9.  Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.

Authors:  Arun Rajasekaran; Ricardo A Franco; Edgar T Overton; Brendan M McGuire; Graham C Towns; Jayme E Locke; Deirdre L Sawinski; Emmy K Bell
Journal:  Kidney Int Rep       Date:  2021-04-25

10.  The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies.

Authors:  Nkengafac Villyen Motaze; Zinhle E Mthombothi; Olatunji Adetokunboh; C Marijn Hazelbag; Enrique M Saldarriaga; Lawrence Mbuagbaw; Charles Shey Wiysonge
Journal:  Vaccines (Basel)       Date:  2021-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.